RG 7652

Drug Profile

RG 7652

Alternative Names: MPSK-3169A; RG-7652

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech; Roche
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Coronary disorders; Hyperlipidaemia; Metabolic disorders

Most Recent Events

  • 24 Jul 2014 Discontinued - Phase-I for Metabolic disorders in Switzerland (unspecified route)
  • 24 Jul 2014 Discontinued - Phase-II for Coronary disorders and Hyperlipidaemia in USA, Canada, Czech Republic, Germany, Hungary, New Zealand, Norway, Slovakia and South Africa (SC)
  • 31 Jul 2013 Genentech completes the phase II EQUATOR trial in Coronary disorders and Hyperlipidaemia in USA, Canada, Czech Republic, Germany, Hungary, New Zealand, Norway, Slovakia and South Africa (NCT01609140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top